Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Axitinib (off Label)

Axitinib + avelumab Phase 2 (MD Anderson)

Pfizer · Phase 2 · Completed · Enrollment 40

Registry id n/r

ArmReported safety
Axitinib + avelumabserious treatment-related adverse events: 29%, primary analysis
Axitinib + avelumab, ACC-I subtypen/r
Axitinib + avelumab, ACC-II subtypen/r

A count stays a count. This page does not turn a count into a percent.